Mosunetuzumabsystemic lupus erythematosusSLEfollicular lymphomaNCT07598396
…lapsed or refractory follicular lymphoma population.Conclusions Mosunetuzumab demonstrated dose-dependent peripheral B-cell depletion and a s…
4articles mentioning drugs
15drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: Mosunetuzumab ×
Mosunetuzumab
This drug is selected. Its supporting articles are shown below.
Articles mentioning Mosunetuzumab
4 articles · page 1 of 1epcoritamabglofitamabmosunetuzumabhaemophagocytic lymphohistiocytosisprogressive multifocal leukoencephalopathydisseminated intravascular coagulationdisseminated tuberculosis
… for several AEs not currently listed in product labelling. For epcoritamab, unlabelled signals included progressive multifocal leukoenceph…
lisocabtagene maraleucelmosunetuzumabglofitamabaxicabtagene ciloleucelBsAbsB-cell lymphomasFLfollicular lymphomaLBCLrelapsed/refractory B-cell lymphomas+2 more
…32%). In FL, CAR-T products such as axicabtagene ciloleucel and lisocabtagene maraleucel achieve CR rates up to 94%, with median durations of remission …
teclistamabtarlatamabtalquetamabepcoritamabelranatamabglofitamabmosunetuzumabblinatumomabbsAbsautoimmune disease
…arlatamab, epcoritamab, glofitamab, mosunetuzumab, talquetamab, teclistamab, and elranatamab. Eligibility criteria were abstracted for excl…